Cart
sales@molnova.com
mTOR inhibitor-1
CAS No. 468747-17-3
mTOR inhibitor-1( —— )
Catalog No. M20101 CAS No. 468747-17-3
C-4 is a potential ATP-competitive inhibitor of mTOR. C-4 could inhibit cell growth and proliferation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 58 | In Stock |
|
| 2MG | 32 | In Stock |
|
| 5MG | 52 | In Stock |
|
| 10MG | 88 | In Stock |
|
| 25MG | 180 | In Stock |
|
| 50MG | 276 | In Stock |
|
| 100MG | 458 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamemTOR inhibitor-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionC-4 is a potential ATP-competitive inhibitor of mTOR. C-4 could inhibit cell growth and proliferation.
-
DescriptionC-4 is a potential ATP-competitive inhibitor of mTOR. C-4 could inhibit cell growth and proliferation.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptormTOR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number468747-17-3
-
Formula Weight363.21
-
Molecular FormulaC16H15BrN2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 70 mg/mL (192.72 mM)
-
SMILESC\C(=N/NC(=O)c1ccc(C)c(Br)c1)c1ccc(O)cc1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Liu J et al. In Silico Discovery of a Small Molecule Suppressing Lung Carcinoma A549 Cells Proliferation and Inducing Autophagy via mTOR Pathway Inhibition. Mol Pharm. 2018 Nov 5;15(11):5427-5436.
molnova catalog
related products
-
mTOR inhibitor-8
mTOR inhibitor-8 is a potent mTOR inhibitor and autophagy inducer with antiviral and antitumor activity. mTOR inhibitor-8 inhibits the growth of A549 cells, which can be used to study non-small cell lung cancer.
-
Y16
Y16 is a G-protein–coupled Rho GEFs inhibitor; works synergistically with Rhosin/G04 in inhibiting LARG-RhoA interaction, RhoA activation, and RhoA-mediated signaling functions.
-
CNX-2006
CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR.
